Journal article
BACE1 as a Therapeutic Target in Alzheimer's Disease: Rationale and Current Status
Genevieve Evin, Christopher Hince
DRUGS & AGING | ADIS INT LTD | Published : 2013
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease of the central nervous system that causes dementia in a large percentage of the aged population and for which there are only symptomatic treatments. Disease-modifying therapies that are currently being pursued are based on the amyloid cascade theory. This states that accumulation of amyloid β (Aβ) in the brain triggers a cascade of cellular events leading to neurodegeneration. Aβ, which is the major constituent of amyloid plaques, is a peptidic fragment derived from proteolytic processing of the amyloid precursor protein (APP) by sequential cleavages that involve β-site APP-cleaving enzyme 1 (BACE1) and γ-secretase. Targeting BACE1 is a..
View full abstractGrants
Funding Acknowledgements
The authors acknowledge funding support from the Judith Jane Mason and Harold Stannett Williams Memorial Foundation. The authors have no conflicts of interest that are directly relevant to the content of this review.